

Disclaimer

Information contained in our presentation is intended solely for your personal reference and is strictly confidential. Such information is subject to change without notice, its accuracy is not guaranteed and it may not contain all material information concerning the company and/or its business. We make no representation or warranty, express or implied, regarding, and assumes no responsibility or liability for, the fairness, accuracy, correctness or completeness of, or any errors or omissions in, any information or opinions contained herein.

In addition, the information contains projections and forward-looking statements that reflect the Company's current views with respect to future events and financial performance. These views are based on current assumptions which are subject to various risks and which may change over time. No assurance can be given that future events will occur, that projections will be achieved, or that the company's assumptions are correct. Actual results may differ materially from those projected. It is not the intention to provide, and you may not rely on this presentation as providing, a complete or comprehensive analysis of the Company's financial or trading position or prospects.

This presentation does not constitute an offer or invitation to purchase or subscribe for any shares and no part of it shall form the basis of or be relied upon in connection with any contract, commitment or investment decision in relation thereto.

٠



Key Achievement

- Revenue up 28.9% yoy to HKD4,743.2 million.
 - Organic growth: 18.7% yoy.
- Gross profit up 37.9% yoy to HKD1,496.5 million.
- Net profit up 48.9% yoy to HKD330.8 million.
 - Tissue revenue up 25.5% yoy to HKD4,583.5 million.
 - Sales volume (tissue) up 25.0% yoy to 320,348 tons.
 - ASP per ton (tissue) was HKD14,308.
- Revenue from Personal Care accounted for 3.4% of total revenue.

Strong

Growth

Promising Tissue Business

Increasing contribution from Personal Care



Financial Highlights

For the 6 months ended 30 June

(HKD million)	2015	2014	Change
Revenue (Note)	4,743.2	3,680.0	+28.9%
Gross profit	1,496.5	1,085.5	+37.9%
Operating profit	468.2	345.7	+35.4%
EBITDA	702.2	521.5	+34.7%
Profit attributable to equity holders of the Company	330.8	222.2	+48.9%
Basic earnings per share (HK cents)	33.1	22.3	+48.4%
Interim dividend per share (HK cents)	5.0	4.0	+25.0%
Foreign exchange gain / (loss)	(30.1)	(33.4)	

Note: Excluding the effect of the acquisition of the SCA business, revenue rose 18.7% yoy.



Revenue by Business Categories



Revenue by Household Paper (Tissue) Categories

For the 6 months ended 30 June 1.9% 3.7% Change (HKD million) 2015 2014 12.0% Toilet roll 2,343.7 2,016.9 +16.2% 1,145.6 838.5 +36.6% Softpack 170.3 132.0 +29.0%Box tissue 548.1 369.7 +48.3%Hanky 25.0% 109.3 79.0 +38.3%Wet wipes 87.5 84.4 +3.7%Paper napkin 3.6% +35.5% 10.1% 132.0 179.0 Others **Total** 4,583.5 3,652.5 +25.5%



Tissue Revenue Mix

Revenue by Distribution Channels





.

Operating Expenditure

Operating Expenditure as % of Sales

1.1% 0.6% 4.9% 6.0% 5.7% 5.1% 21.2% 20.2% 15.4% 14.3% 1H2014 1H2015 1H2014 1H2015 R&D expense ratio Administrative expenses ratio

- Selling & marketing expenses ratio
- Total administrative expense ratio was 6.0%.
 - 1.1% of sales was spent on R&D.
 - General administrative expenses ratio dropped by 0.2 p.pt to 4.9%.
- Selling and marketing expenses ratio increased 1.1 p.pt., as more resources were allocated to build the brands and develop the personal care business.

 Obtained the hi-tech enterprise qualification for Vinda Paper (China) Co. in 1H2015.

Effective Tax Rate

• Effective tax rate dropped by 1.0 p.pt.

Key Financial Indicators

		U 0	
	As at 30 Jun 2015	As at 30 Jun 2014	
Debtors Turnover Days	45	47	
Creditors Turnover Days	71	70	
Stock Turnover Days	108	109	
(HKD million)	As at 30 Jun 2015	As at 31 Dec 2014	
Total borrowings (including SCA shareholder loan)	4,527.7	4,464.8	
Total borrowings (excluding SCA shareholder loan)	1,957.3	2,434.7	
Cash and cash equivalents*	514.0	721.6	
Net gearing ratio** (%)	75.7%	73.7%	
Net debt to EBITDA***	2.9	3.1	
Interest coverage**** (times)	7.4	8.2	

- Adopted cash pooling system so that cash position was lowered to HKD514.0 million.
- Total outstanding shareholder loans from SCA as at 30 Jun 2015: approximately HKD2.6 billion.
- Total unutilized credit facilities (including unutilized shareholder loan) as at 30 Jun 2015: approximately HKD7.3 billion.

- *** Net debt to EBITDA: Total borrowings minus cash and cash equivalents/EBITDA
- *** *Interest coverage: EBIT/interest (times), excluding exchange rate factor.



^{*} Incl. Restricted bank deposit.

^{**} Net gearing ratio: Total borrowings (incl. SCA shareholder loan) less bank balances and cash and restricted deposits / total shareholders' equity.



Ensure stable growth in tissue and roll out *Tempo* nationwide

Increase awareness and popularity of personal care brands

Priorities in 2H2015

Achieve more synergies with SCA

Penetrate to lower tier cities via distributors & echannel; expand baby stores & nursing home

an Results Announcement 2015



** 2014 market size growth rate estimated by China National Household Paper Industry Association

Online and Specialized Sales

E-Commerce

Ranking No.1 in terms of market share at major e-commerce platforms

Enhance e-commerce platform to broaden market coverage by reaching new markets through Internet

Specialized Sales

Speed up the introduction of new personal care products to the existing sales and distribution channels

Establish specialized sales channels at baby care shops, elderly's homes and hospitals

Advanced & Efficient Production Sites

Annual Designed Production Capacity

for Tissue (Tons)

Production Site	1H2015	2015 end
Xinhui, Sanjiang	380,000	380,000
Hubei	180,000	180,000
Zhejiang	150,000	150,000
Shandong	50,000	80,000
Liaoning	55,000	55,000
Sichuan	45,000	75,000
Beijing	30,000	30,000
Total	890,000	950,000

- Originally planned to add 90,000 tons of capacity in Shandong and Sichuan by Q42015. Due to the delay in equipment supply, 30,000 tons of such capacity to be put into operation in 2016.
- To build our own production facilities for incontinence care product and expected to commence production in the second half of 2016.

Mid-Long Term Goal



In mid to long run, to become.....

- Leader in Tissue & Incontinence Care category respectively
- **First tier brand** in Baby Care & Feminine Care category respectively

Personal care businesses to contribute 20% of Group's total revenue in mid to long term



